PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Market Cap	$7.68M	P/E Ratio	N/A
52W High	$28.44	52W Low	$6.00
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	76.8%	52W Position	0.6%
Overall Score	43	Value Score	60
Quality Score	44	Technical Score	27

EPS Current Est	$-3.19	EPS Next Est	$-3.19
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PAVM	$6.14	-3.91%	13.11K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PAVM	$6.14	-3.9%	13.11K
3
4
5
6

PAVM

PAVM

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get PAVmed Inc. Data in Excel

Get PAVmed Inc. Data in Excel